Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 1529 • ACR Convergence 2022
Clinical Nailfold Capillaroscopy Using Dinolite Microscope in Patients with Systemic Sclerosis
Krishnasai Abhishek Madathanapalli¹, Alyssa Williams², Baran Ilayda Gunes², Francis Perry Wilson³, John Pauling⁴, Robyn Domsic⁵, Lan Yu⁶ and Monique Hinchcliff⁷, ¹University of Connecticut School of Medicine, Hartford, CT, ²Yale University, New Haven, CT, ³Yale school of medicine, New Haven, CT, ⁴North Bristol NHS Trust, Bristol, United Kingdom, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: The clinical importance of nailfold capillaroscopy (NFC) has grown since its inclusion in the 2013 ACR/EULAR Classification Criteria for systemic sclerosis (SSc), yet few…
Abstract Number: 1557 • ACR Convergence 2022
Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center
Belén Atienza-Mateo¹, Alfonso del Peral-Fanjul², Veronica Pulito-Cueto³, Diana Prieto-Peña¹, Miguel Ángel González-Gay⁴ and Ricardo Blanco⁵, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, Spain, ³IDIVAL, Santander, Spain, ⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and mucocutaneous manifestations of Behçet's disease (BD) are globally recognized and widely studied [Arthritis Rheumatol. 2019 Dec;71(12):2081-2089, Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl…
Abstract Number: 1773 • ACR Convergence 2022
Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
Rashmi Dhital¹, Monica Guma², Thuthiri Lwin³, Amar Suwal⁴ and Brian Pedersen¹, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³University of California San Diego, San Diego, CA, ⁴Reading Hospital, Tower Health, Reading, PA
Background/Purpose: The prevalence of Raynaud's phenomenon (RP) in the general population is ~3-5%, of which 80–90% are primary. Autoimmune diseases are the most common causes…
Abstract Number: 2036 • ACR Convergence 2022
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
Andres Martinez¹, Julieta Morbiducci¹, Constanza Arguissain¹, Maria Tamborenea¹, Marisel Bejarano², Lucia Castorino¹ and Anastasia Secco¹, ¹Rivadavia Hospital, Buenos Aires, Argentina, ²Rivadavia´s Hospital, Buenos Aires, Argentina
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
Abstract Number: 0399 • ACR Convergence 2021
Nailfold Videocapillaroscopy Findings and Associations with Organ Involvement in Mixed Connective Tissue Disease
Camille Kasser, Gonçalo Boleto, Yannick Allanore and Jerome Avouac, Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition characterized by Raynaud’s phenomenon, positivity of antibodies targeting the U1 small nuclear ribonucleoprotein particle…
Abstract Number: 0400 • ACR Convergence 2021
Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
John Pauling¹, Lesley Ann Saketkoo², Dinesh Khanna³, Christopher Denton⁴, Tracy Frech⁵, Ariane Herrick⁶, Laura Hummers⁷, Ami Shah⁸ and Robyn Domsic⁹, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ³University of Michigan, Ann Arbor, MI, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁵University of Utah, Salt Lake City, UT, ⁶University of Manchester, Salford, United Kingdom, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The episodic and uniquely personalised nature of Raynaud’s phenomenon (RP) has led to reliance upon self-report to capture how patients ‘feel’ and ‘function’. Existing…
Abstract Number: 0401 • ACR Convergence 2021
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…
Abstract Number: 0410 • ACR Convergence 2021
Long-term Outcomes of Vascular Grafting of Medium Sized Vessels of the Wrist and Hand in Patients with Medication Refractory Systemic Sclerosis Related Raynaud’s Phenomenon at the University of Pennsylvania from 2009-2019
Nora Sandorfi¹, Chris Derk² and Nora Hajnoczky³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Albert Einstein Healthcare Network, Wallingford, PA
Background/Purpose: Raynaud’s phenomenon (RP) seen in patients with an underlying autoimmune rheumatic disorder have both functional and structural dysfunction at the microvascular level and in…
Abstract Number: 0499 • ACR Convergence 2021
Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome instrument devised to assess the severity and impact of SSc-RP.…
Abstract Number: 1365 • ACR Convergence 2021
Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Amel Eman Abdulle², Anniek Van Roon², Alja J. Stel², Harry Van Goor², Andries Smit², Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Raynaud’s Phenomenon (RP) leading to repetitive ischaemia and reperfusion (IR) stress, is the first recognisable sign of systemic sclerosis (SSc). Although RP has been…
Abstract Number: 1376 • ACR Convergence 2021
Outcome Reporting in Systemic Sclerosis-Related Digital Ulcers: A Scoping Review
Michael Hughes¹, Nancy Maltez², Edith Brown³, Virginia Hickey⁴, Heiyoung Park⁵, Beverley Shea², John Pauling⁶, Susanna Proudman⁷, Peter Merkel⁸ and Ariane Herrick⁹, ¹Tameside and Glossop Integrated NHS Foundation Trust, Manchester, United Kingdom, ²University of Ottawa, Ottawa, ON, Canada, ³n/a, Manchester, United Kingdom, ⁴n/a, Adelaide, Australia, ⁵5. National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷University of Adelaide, Medindie, Australia, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Manchester, Salford, United Kingdom
Background/Purpose: Digital ulcers (DUs) are a major cause of pain and disability in patients with systemic sclerosis (SSc). Despite the availability of a range of…
Abstract Number: 1387 • ACR Convergence 2021
Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis
Devender Bairwa¹, Chengappa Kavadichanda², sanket Shah³, Anoop Mathew¹, saikumar dunga³, Aishwarya Gopal³, Molly Mary Thabah¹ and VirSingh Negi¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India, ²JIPMER, Pondicherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Microvascular dysfunction is a key and determining feature of scleroderma (SSc). But contrary to earlier belief there is emerging evidence to suggest co-occurrence of…
Abstract Number: 1635 • ACR Convergence 2021
Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?
Claudette Farenhorst¹, Anniek Van Roon¹, Anne van Gessel¹, Alja Stel¹, Hendrika Bootsma², Wineke Armbrust¹ and Douwe J Mulder¹, ¹University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Nailfold capillary microscopy (NCM) is a cornerstone in the diagnosis of Systemic Sclerosis (SSc) in adulthood. Although Raynaud’s phenomenon (RP) is common in childhood,…
Abstract Number: 0180 • ACR Convergence 2021
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis
Attila Feher¹, Nabil Boutagy¹, Evangelos Oikonomou¹, Stephanie Thorn¹, Yi-Hwa Liu¹, Edward Miller¹, Albert Sinusas¹ and Monique Hinchcliff², ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Westport, CT
Background/Purpose: To investigate the association between Raynaud phenomenon (RP) and coronary microvascular dysfunction, we measured myocardial flow reserve (MFR) using positron emission tomography/computed tomography (PET/CT)…
Abstract Number: 0391 • ACR Convergence 2021
High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time
Elizabeth Marjanovic¹, Calvin Heal¹, Tonia Moore¹, Joanne Manning², Sarah Wilkinson¹, Graham Dinsdale², Mark Dickinson¹, Jack Wilkinson¹, Ariane Herrick³ and Andrea Murray¹, ¹University of Manchester, Manchester, United Kingdom, ²Salford Royal NHS Foundation Trust, Manchester, United Kingdom, ³University of Manchester, Salford, United Kingdom
Background/Purpose: There are currently no validated objective measures of systemic sclerosis (SSc)-related skin thickening and this hampers clinical trials of potential new treatments. The modified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].